Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the DiffuSphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's DiffuSphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.
Story Continues
Notice Regarding Forward-looking Statements and Information
This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "suggests", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes", "potential" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the expected enrollment and number of sites for the Phase 2b portion of the RESOLVE study; the expected parameters of the RESOLVE study; the availability of topline data and release of additional long-term data with higher doses and timing thereof; the Company's product candidates, including their expected benefits to patients with respect to safety, tolerability, efficacy and duration; the expectations around proceeding to clinical trials for the Company's product candidates; the results gathered from studies and trials of Eupraxia's product candidates; the potential for the Company's technology to impact the drug delivery process; potential market opportunity for the Company's product candidates; and potential pipeline indications. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its product candidates and services; the potential impact of tariffs on the cost of the Company's active pharmaceutical ingredients and clinical supplies of EP-104IAR and EP-104GI; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise.
For investor and media inquiries, please contact:
Danielle Egan, Eupraxia Pharmaceuticals Inc.
778.401.3302
degan@eupraxiapharma.com
or
Kevin Gardner, on behalf of:
Eupraxia Pharmaceuticals Inc.
617.283.2856
kgardner@lifesciadvisors.com
SOURCE Eupraxia Pharmaceuticals Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Highlights of the Nike Deal, Broadcast Partnerships, Kit Sponsorships, and Stadium Naming Rights
Explore the "Business of the NWSL 2025," a detailed report on the women's soccer league's media and sponsorship landscapes. Discover insights on $39.5M in league sponsorship, $60M in media rights, and $66.46M in team sponsorship. Learn about market viewership, team profiles, and social media metrics. Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The "The Business of the National Women's Soccer League 2025" report has been added to offering. The main aims of this report is to highlight commercial landscape across NWSL. The report aims to break down the key commercial revenue streams for the league and its affiliated teams. It goes into detail on the key partnerships including its centralized rights with Nike, its four main US broadcasters, front-of-shirt rights, sleeve partnerships and stadium naming "Business of the NWSL 2025" report is part of the the analyst's 'Business of' series of sport competition profiles. The report takes a deep dive into the premier competition for women's domestic soccer in the United States. The report explores the biggest rights across the league, specifically looking at the main media and sponsorship rights attached to the NWSL, as well the main sponsorship rights and annual values of the 14 competing teams. The report also looks at market viewership, profiles individual teams and offers social media following comparisons against teams, other American sports leagues and other soccer NWSL stands to generate $39.5 million from league sponsorship this season. Home market media rights worth $60 million across four main broadcaster deals. Team sponsorship in the league worth $66.46 million in Highlights Overview of the media rights landscape. Global media and sponsor partners explored. Breakdown of the sponsorship deals including annual values. Individual team profiles. Team market comparison by sponsorship. Connected social media followers. Reasons to Buy Soccer is a growing sport in the United States as the country build towards jointly hosting (with Canada and Mexico) the 2026 men's FIFA World Cup . The NWSL, alongside the WNBA (basketball) is the most popular women's sports leagues in the United States and has produced many of the best players in the world over the past decade. Key Topics Covered: 1. Overview2. Media landscape3. League sponsorship landscape4. Kit supplier landscape5. Front-of-shirt landscape6. Sleeve landscape7. Back-of-shirt landscape8. Stadium naming rights landscape9. Team sponsorship overview10. Additional revenue & social media11. AppendixKey Data Tables Home market broadcasters Regional broadcasters International broadcasters NWSL ticket revenue For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
15 minutes ago
- Yahoo
How Greg Schiano built Rutgers football's infrastructure to adapt to changing landscape
As the wayward search for Rutgers' new athletics director appears to finally be close to an end, Greg Schiano's football program will begin training camp having been unaffected and undeterred by what transpired over the last year. The chaos that's engulfed the Rodkin Center hasn't moved across Sutphen Road to infiltrate the Hale Center. And that's not a coincidence. Schiano since he's been back has run his program in his vision with the personnel and infrastructure that he sees fit. As the landscape of college sports – especially college football – has evolved with Name, Image and Likeness, the transfer portal and now revenue sharing, that infrastructure has only become more important. It's also become bigger. But the freedom Schiano has to lead his program without interference has helped insulate it from an AD search that became a punchline nationally – its previous leading candidate, Brian Lafemina, according to NJ Advance Media pulled his name from consideration in recent weeks. The university has now zeroed in on Keli Zinn, the executive deputy director of athletics and chief operating officer at Louisiana State, according to reports. When asked about the long search last week in Las Vegas at Big Ten Media Days, Schiano said he hadn't spent much time worrying about the search. Had it affected anything? 'Not our operation,' said Schiano, who's beginning his sixth season since returning to Rutgers. More: Rutgers is targeting LSU administrator as next athletics director, per reports Rutgers football's infrastructure While it undoubtedly would help Schiano to have an athletics director who could help him raise funds – something he's never had during his second stint – it's not something that's stopping him. Schiano's program has increasingly started to look like an NFL organization. His two years as the head coach of the Tampa Bay Buccaneers in 2012 and 2013 gave him an up-close, inside look at what it needs. NFL organizations have college personnel and pro personnel to evaluate both groups of players. Schiano's program has groups to evaluate high school players and college players so it's ready to jump when anyone enters the portal. Schiano's been diligent about how he's built the operation. 'Certainly we need more people to help with evaluations but we've kind of reorganized our entire population,' Schiano said. 'My whole thing has always been measure twice and cut once. I don't want to just react, I'd rather be a little bit later and get it right than have to be the first out of gate. I don't want to be last but certainly don't need to be first. I've observed a lot of other people, what they've done. Things I think are good, things that are not. Certainly from my own experience I had an idea of how I wanted to do it.' 'Comfortable with the team we have' Schiano credited the team he's assembled to help lead it: Chief of Staff Kevin MacConnell, assistant general manager for finance Jordan Wolkstein, assistant general manager for personnel Eric Josephs, and assistant athletic director for football Will Gilkison, who helps run the ins and outs of program operations. Wolkstein's role helping to oversee contracts and compensation for players shows just how much college football has changed, but it's also a necessity. When it comes to paying players and roster construction to stay within a budget, that's another area Schiano's time in the NFL helped prepare him for. 'I think it helps a lot,' Schiano said. 'I think it just helps with the comfortability of dealing with finance as it ties to football. I think you have to some discipline. We've had some players that if we could've spent a little more, we could've probably gotten them. To me the most important thing is your own team. You're around them every day, you know who they are. So where you can't afford to make mistakes is on your own team. That's the one you should know. Every time you step outside your organization there's some unknown there.' Every year Schiano's program has evolved. Every year it's looked more and more like a pro organization to adapt to the changes in college football. He's built it in his vision. At some point Rutgers will hire an athletics director, but until it does operations inside the Hale Center continue to run smoothly. 'We really feel comfortable with the team that we have,' Schiano said. 'We do have to continue to strategically add people to build the infrastructure but I want to make sure they're the right people.' This article originally appeared on Rutgers football: Greg Schiano has built program to adapt to changes
Yahoo
an hour ago
- Yahoo
Bank of Canada widely expected to hold key rate steady amid trade uncertainty
OTTAWA — Avery Shenfeld doesn't think the Bank of Canada will cut its benchmark interest rate at its decision on Wednesday, but if it does, he said it will be a "pleasant surprise." "There's always a chance that they'll surprise with the rate cut," the chief economist of CIBC said. "But I'm not holding out that much hope." Most economists are also expecting the Bank of Canada will hold its policy rate steady at 2.75 per cent for a third consecutive decision later this week. As of Friday afternoon, financial markets were placing odds of a quarter-point rate cut on Wednesday at just seven per cent, according to LSEG Data & Analytics. Stubbornness on the inflation front and surprise strength in the labour market have quashed arguments for further easing since the central bank's June decision. The Canadian economy gained an unexpected 83,000 jobs in June, Statistics Canada reported earlier this month, driving the unemployment rate lower for the first time since January. A few days later, StatCan reported annual inflation ticked up to 1.9 per cent last month while the Bank of Canada's closely watched core inflation figures held stubbornly around three per cent. "Overall, sticky inflation readings, a weakening but relatively resilient economic backdrop and prospects for larger fiscal spending are reasons why we do not expect the BoC will cut again in this cycle," RBC economists Claire Fan and Abbey Xu wrote in a note Friday. But Shenfeld's call for a lower policy rate — CIBC expects two more quarter-point drops before the Bank of Canada is done — isn't based on what's happened in the economy, it's about what's on the horizon. Outside of the June jobs jump, the labour market is still broadly weak with the unemployment rate at 6.9 per cent, Shenfeld noted. He also expects Canada's tariff dispute with the United States led to an economic contraction in the second quarter of the year. All told, there's enough "slack" building in the economy to take steam out of inflation in the months to come, Shenfeld said. The Bank of Canada's own second-quarter business outlook survey released last week suggests that many firms are opting to absorb higher costs from tariffs, rather than pass them on to consumers who may be reining in spending amid economic uncertainty. Shenfeld said that's a sign that tariff impacts "won't extend into a more persistent inflation issue." He said that once the central bank gains enough confidence that any tariff-induced inflation pressures will be short-lived, monetary policymakers should feel confident enough to lower interest rates. "I think at this point they know enough to rule out the worst-case scenario on trade," Shenfeld said. Bank of Canada governor Tiff Macklem has explicitly said monetary policymakers are being less forward-looking than usual in the trade war. The central bank didn't publish a traditional forecast for the economy in its April monetary policy report, instead offering two scenarios for how tariffs could hit the economy. Jimmy Jean, chief economist at Desjardins, said he believes the Bank of Canada will have gathered enough clarity on the trade front to return to formal forecasts in this week's MPR. "The uncertainty is there for everyone to recognize. But there's a point where you've got to sort of, stick your neck out and make the proper caveats," Jean said. Tariff deadlines continue to hover over the Bank of Canada's head — U.S. President Donald Trump has threatened to levy tariffs of 35 per cent on Canadian imports starting Friday if a trade deal isn't reached before then, though CUSMA-compliant goods are expected to be exempt from the duties. Some forecasters, including RBC, expect the Bank of Canada is already done rate cuts and will turn the job of stimulating the economy through the trade war over to federal and provincial governments. While Jean also believes the central bank will opt to hold rates again on Wednesday, he said the bank's next decision in September is an "open possibility" for a cut. Trump's sectoral tariffs targetting Canada's steel, aluminum and copper industries are of particular concern for Ontario and Quebec, Jean said. If those tariffs are sustained, he argued more rate cuts from the Bank of Canada will be warranted to cushion the economic hit. In addition to some sector-specific relief, the federal government has moved in recent months to ramp up Canada's defence and infrastructure funding — spending that could offer fiscal, rather than monetary, support for the economy. But Jean said Desjardins is expecting that lift to come over the ensuing years, not months, opening a window for the Bank of Canada to lower rates in the near-term. "We think, despite those measures being in the pipeline, the Bank of Canada will still in September have a valid reason to cut interest rates," he said. This report by The Canadian Press was first published July 28, 2025. Craig Lord, The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
